<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Bio</title>
	<atom:link href="http://www.tapanray.in/tag/bio/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Scandalizing Biosimilar Drugs With Safety Concerns</title>
		<link>http://www.tapanray.in/scandalizing-biosimilar-drugs-with-safety-concerns/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=scandalizing-biosimilar-drugs-with-safety-concerns</link>
		<comments>http://www.tapanray.in/scandalizing-biosimilar-drugs-with-safety-concerns/#comments</comments>
		<pubDate>Mon, 25 Aug 2014 00:00:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[12]]></category>
		<category><![CDATA[badmouthing]]></category>
		<category><![CDATA[Bio]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[concerns]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[GPhA]]></category>
		<category><![CDATA[Hamburg]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[INN]]></category>
		<category><![CDATA[Investor]]></category>
		<category><![CDATA[proposal]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[scandalizing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[Year]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5772</guid>
		<description><![CDATA[With the patent expiry of exorbitantly priced biologic medicines, introduction of biosimilar drugs are expected to improve their access to millions of patients across the world, saving billions of dollars in healthcare costs in the subsequent years. According to an &#8230; <a href="http://www.tapanray.in/scandalizing-biosimilar-drugs-with-safety-concerns/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/scandalizing-biosimilar-drugs-with-safety-concerns/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biosimilars: Creating new vistas of opportunities for Indian Bio Pharmaceutical players in the global market.</title>
		<link>http://www.tapanray.in/biosimilars-creating-new-vistas-of-opportunities-for-indian-bio-pharmaceutical-players-in-the-global-market/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=biosimilars-creating-new-vistas-of-opportunities-for-indian-bio-pharmaceutical-players-in-the-global-market</link>
		<comments>http://www.tapanray.in/biosimilars-creating-new-vistas-of-opportunities-for-indian-bio-pharmaceutical-players-in-the-global-market/#comments</comments>
		<pubDate>Thu, 31 Dec 2009 01:00:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bio]]></category>
		<category><![CDATA[biosimilars]]></category>
		<category><![CDATA[Creating]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[pathway]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[vistas]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=682</guid>
		<description><![CDATA[Biosimilar or follow-on biologic drugs market is fast evolving across the world with varying degree of pace and stages of developments. The global market for Bio-pharmaceuticals was around US$ 120 billion in 2008, as reported by IMS. However, total turnover &#8230; <a href="http://www.tapanray.in/biosimilars-creating-new-vistas-of-opportunities-for-indian-bio-pharmaceutical-players-in-the-global-market/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/biosimilars-creating-new-vistas-of-opportunities-for-indian-bio-pharmaceutical-players-in-the-global-market/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
